{"id":77529,"date":"2026-08-31T14:07:54","date_gmt":"2026-08-31T06:07:54","guid":{"rendered":"https:\/\/flcube.com\/?p=77529"},"modified":"2026-08-31T14:08:30","modified_gmt":"2026-08-31T06:08:30","slug":"leaderna-therapeutics-closes-series-a-led-by-grand-view-capital-to-advance-oligonucleotide-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77529","title":{"rendered":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Leaderna Therapeutics<\/strong> announced the completion of its <strong>Series A+ financing round<\/strong>, invested exclusively by <strong>Grand View Capital<\/strong> through its <strong>Xiamen Ruilu Fund<\/strong>. Proceeds will fund clinical development of the company&#8217;s pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.<\/p>\n\n\n\n<h2 id=\"h-financing-milestone\" class=\"wp-block-heading\">Financing Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Company<\/td><td><strong>Leaderna Therapeutics<\/strong><\/td><\/tr><tr><td>Round<\/td><td>Series A+<\/td><\/tr><tr><td>Sole Investor<\/td><td><strong>Grand View Capital<\/strong> (Xiamen Ruilu Fund)<\/td><\/tr><tr><td>Date<\/td><td>Late Aug 2026<\/td><\/tr><tr><td>Use of Proceeds<\/td><td>Clinical pipeline advancement, extrahepatic delivery optimization, preclinical expansion<\/td><\/tr><tr><td>Next Steps<\/td><td>Progress first\u2011in\u2011class small nucleic acid candidates into clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-technology-platforms\" class=\"wp-block-heading\">Company Profile &amp; Technology Platforms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2022, focused on oligonucleotide drug discovery and development<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Major chronic conditions including metabolic, cardiovascular, and cerebrovascular diseases<\/li>\n\n\n\n<li><strong>Pipeline Strategy:<\/strong> Comprehensive product layout targeting differentiated, best\u2011in\u2011class or first\u2011in\u2011class small nucleic acid therapeutics<\/li>\n\n\n\n<li><strong>Platform 1 \u2014 NEATL:<\/strong> Novel Delivery and Oligonucleotide\u2011Enhanced Modification Technology<\/li>\n\n\n\n<li><strong>Platform 2 \u2014 LOCATED:<\/strong> Lipid\u2011Conjugated Extrahepatic Delivery Technology<\/li>\n\n\n\n<li><strong>Platform 3 \u2014 DIRECT:<\/strong> Single\u2011Molecule Dual\u2011Targeting Interference Technology<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-focus-areas\" class=\"wp-block-heading\">Strategic Focus Areas<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Clinical Advancement<\/td><td>Progress first\u2011in\u2011class small nucleic acid candidates into the clinic<\/td><\/tr><tr><td>Platform Optimization<\/td><td>Enhance extrahepatic delivery capabilities, a key bottleneck in oligonucleotide drug development<\/td><\/tr><tr><td>Portfolio Expansion<\/td><td>Broaden preclinical pipeline across metabolic and cardiometabolic indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The financing underscores continued investor appetite for China&#8217;s oligonucleotide therapeutics sector, where delivery technology \u2014 particularly extrahepatic targeting beyond the liver \u2014 has emerged as a critical differentiator. Leaderna&#8217;s three proprietary platforms position it to pursue indications where established GalNAc\u2011liver delivery approaches reach their limits.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sector Momentum:<\/strong> Sustained private capital flows into China&#8217;s small nucleic acid space signal confidence in the modality&#8217;s commercial trajectory<\/li>\n\n\n\n<li><strong>Technology Moat:<\/strong> Proprietary delivery and dual\u2011targeting platforms offer defensibility in a crowded oligonucleotide landscape<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Extrahepatic delivery capability could open indications underserved by current liver\u2011centric approaches<\/li>\n\n\n\n<li><strong>Investor Signal:<\/strong> Exclusive backing by Grand View Capital reflects conviction in Leaderna&#8217;s platform breadth and pipeline differentiation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding Leaderna Therapeutics&#8217; clinical development, technology optimization, and pipeline expansion. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77530,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,4908],"tags":[314,64],"class_list":["post-77529","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-pic","tag-leaderna-therapeutics","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand View Capital through its Xiamen Ruilu Fund. Proceeds will fund clinical development of the company&#039;s pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77529\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline\" \/>\n<meta property=\"og:description\" content=\"Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand View Capital through its Xiamen Ruilu Fund. Proceeds will fund clinical development of the company&#039;s pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77529\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T06:07:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T06:08:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline\",\"datePublished\":\"2026-08-31T06:07:54+00:00\",\"dateModified\":\"2026-08-31T06:08:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529\"},\"wordCount\":386,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3103.webp\",\"keywords\":[\"Leaderna Therapeutics\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77529#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77529\",\"name\":\"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3103.webp\",\"datePublished\":\"2026-08-31T06:07:54+00:00\",\"dateModified\":\"2026-08-31T06:08:30+00:00\",\"description\":\"Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand View Capital through its Xiamen Ruilu Fund. Proceeds will fund clinical development of the company's pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77529\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3103.webp\",\"width\":1080,\"height\":608,\"caption\":\"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77529#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand View Capital through its Xiamen Ruilu Fund. Proceeds will fund clinical development of the company's pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77529","og_locale":"en_US","og_type":"article","og_title":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline","og_description":"Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand View Capital through its Xiamen Ruilu Fund. Proceeds will fund clinical development of the company's pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.","og_url":"https:\/\/flcube.com\/?p=77529","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T06:07:54+00:00","article_modified_time":"2026-08-31T06:08:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77529#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77529"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline","datePublished":"2026-08-31T06:07:54+00:00","dateModified":"2026-08-31T06:08:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77529"},"wordCount":386,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77529#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp","keywords":["Leaderna Therapeutics","RNAi \/ ASO"],"articleSection":["Company","Deals","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77529#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77529","url":"https:\/\/flcube.com\/?p=77529","name":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77529#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77529#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp","datePublished":"2026-08-31T06:07:54+00:00","dateModified":"2026-08-31T06:08:30+00:00","description":"Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand View Capital through its Xiamen Ruilu Fund. Proceeds will fund clinical development of the company's pipeline \u2014 including first\u2011in\u2011class small nucleic acid products \u2014 while accelerating optimization of its extrahepatic delivery platforms and expanding its preclinical portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77529#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77529"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77529#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp","width":1080,"height":608,"caption":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77529#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3103.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77529"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77529\/revisions"}],"predecessor-version":[{"id":77531,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77529\/revisions\/77531"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77530"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}